FNA

Fannie Mae Priced $381 Million Multifamily Social DUS REMIC (FNA 2022-M1S) Under Its GeMS Program

Retrieved on: 
Wednesday, July 6, 2022
Fannie Mae, OTCQB, Front commun des personnes assistées sociales du Québec, Senior, MBS, AMI, History, Housing, FNA, FNMA, Program, Sustainalytics, Renewable energy, Commercial property, Gemstone

WASHINGTON, July 6, 2022 /PRNewswire/ -- Fannie Mae (OTCQB: FNMA) priced a $381 million Multifamily Social DUS REMIC under its Fannie Mae Guaranteed Multifamily Structures (Fannie Mae GeMS) program on June 23, 2022.

Key Points: 
  • WASHINGTON, July 6, 2022 /PRNewswire/ -- Fannie Mae (OTCQB: FNMA) priced a $381 million Multifamily Social DUS REMIC under its Fannie Mae Guaranteed Multifamily Structures (Fannie Mae GeMS) program on June 23, 2022.
  • FNA 2022-M1S marks the sixth Fannie Mae GeMS issuance of 2022.
  • "The M1S is our first social GeMS of 2022 and the third in GeMS history," said Dan Dresser, Senior Vice President, Multifamily Capital Markets and Pricing, Fannie Mae.
  • "The collateral backing the M1S reflects the social criteria in our Sustainable Bond Framework, in support of affordable housing," said Lisa Bozzelli, Senior Director, Multifamily Capital Markets, Fannie Mae.

New Data Show Strong Performance of Veracyte’s Afirma GSC in Real-World Clinical Practice

Retrieved on: 
Monday, June 20, 2022
Biotechnology, Health Technology, Genetics, Health, ENDO, Time, Laboratory, Cancer, LDT, FDA, Investor, Form 10-Q, Annual report, Malignancy, Thyroid cancer, Forward-looking statement, Meta-analysis, American Thyroid Association, FNA, SEC, CV, GSC, Biopsy, Twitter, Incidence, Patient, Endocrinology, Health, Diagnosis, Conference, Annual conferences, Risk, Pharmaceutical industry, Medical device

The Afirma GSCs clinical validation study provided high-quality evidence of our tests ability to rule out malignancy in indeterminate thyroid nodules to help these patients avoid unnecessary surgery.

Key Points: 
  • The Afirma GSCs clinical validation study provided high-quality evidence of our tests ability to rule out malignancy in indeterminate thyroid nodules to help these patients avoid unnecessary surgery.
  • An example of a forward-looking statement includes, among others, that the Afirma GSC can improve thyroid cancer diagnosis in patients with indeterminate thyroid nodules.
  • The Afirma GSC is available as part of Veracytes CLIA-validated laboratory developed test (LDT) service.
  • Veracyte, the Veracyte logo and Afirma are registered trademarks of Veracyte, Inc. and its subsidiaries in the U.S. and selected countries.

Paragon 28 Launches Monkey Rings™ Circular External Fixation System

Retrieved on: 
Thursday, June 9, 2022
General Health, Health, Other Health, Medical Devices, Paragon, Arthritis, Foot, Chicken feet, Trauma, Bunion, Jungle, Multimedia, Charcot foot, Sandwich plate system, Recurrence, FNA, P28, Patient, Hospital, NYSE, Ankle, APEX, Surgeon, Monkey, Deformity, Medical imaging

Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced the launch of its Monkey Rings Circular External Fixation System for trauma, deformity correction, and limb salvage.

Key Points: 
  • Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced the launch of its Monkey Rings Circular External Fixation System for trauma, deformity correction, and limb salvage.
  • View the full release here: https://www.businesswire.com/news/home/20220613005025/en/
    Monkey Rings Circular External Fixation System (Graphic: Business Wire)
    The Monkey Rings Circular External Fixation System is designed to use external wires and screws that can be fixed into bone to maintain anatomic position while providing stability, preservation of soft tissue, and allow for adjustability and functionality.
  • The Monkey Rings System allows hospitals and surgeons to work with a single vendor for internal fixation, external fixation, wound care, and biologics.
  • The addition of the Monkey Rings Circular External Fixation System bolsters Paragon 28's product offering which includes the Silverback Ankle Fusion Plating System, Gorilla R3CON Plating System, Joust Beaming Screw System, APEX 3D Total Ankle Replacement System, and Phantom TTC Fusion Nail Systems.

Paragon 28 Launches TenoTac™ 2.0 Soft Tissue Stabilization System for Hammertoe and Soft Tissue Repair

Retrieved on: 
Thursday, May 19, 2022
Biotechnology, Health, Surgery, Medical Devices, Paragon, Chicken feet, Foot, JAWS, FNA, Surgeon, Multimedia, Bunion, Contracture, Recurrence, Charcot foot, Titanium, Ankle, NYSE, Hammer toe

Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced further expansion of its hammertoe and soft-tissue portfolio with the launch of its TenoTac 2.0 Soft Tissue Fixation System.

Key Points: 
  • Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced further expansion of its hammertoe and soft-tissue portfolio with the launch of its TenoTac 2.0 Soft Tissue Fixation System.
  • The TenoTac 2.0 Soft Tissue Fixation System uses a titanium threaded implant and was designed to allow for greater capture of soft tissue, streamlined tensioning, and improved fit to the bony surface.
  • TenoTac 2.0 adds to our growing portfolio of soft tissue products and the Hammertoe segment, with opportunities for significant improvements in patient outcomes.
  • The addition of the TenoTac 2.0 Soft Tissue Fixation System bolsters Paragon 28s hammertoe product offering, which includes the Paratrooper Plantar Plate System, HammerTube Hammertoe System, Mini-Monster Screw System, and JAWS Staple System.

Fannie Mae Priced $720 Million Multifamily DUS REMIC (FNA 2022-M10) Under Its GeMS Program

Retrieved on: 
Tuesday, May 17, 2022
Senior, MBS, FNA, Fannie Mae, M10, DUS, OTCQB, FNMA, Commercial property

WASHINGTON, May 17, 2022 /PRNewswire/ -- Fannie Mae (OTCQB: FNMA) priced a $720 million Multifamily DUS REMIC under its Fannie Mae Guaranteed Multifamily Structures (Fannie Mae GeMS) program on May 11, 2022.

Key Points: 
  • WASHINGTON, May 17, 2022 /PRNewswire/ -- Fannie Mae (OTCQB: FNMA) priced a $720 million Multifamily DUS REMIC under its Fannie Mae Guaranteed Multifamily Structures (Fannie Mae GeMS) program on May 11, 2022.
  • FNA 2022-M10 marks the fifth Fannie Mae GeMS issuance of 2022.
  • "The M10 provided an opportunity to buy discounted, 10-year cash flows with 100% of any future prepayment premiums on the underlying MBS," said Dan Dresser, Senior Vice President, Multifamily Capital Markets and Pricing, Fannie Mae.
  • All classes of FNA 2022-M10 are guaranteed by Fannie Mae with respect to the full and timely payment of interest and principal.

Paragon 28 Expands Soft Tissue Portfolio with Grappler™ Suture Anchor System Launch

Retrieved on: 
Tuesday, May 17, 2022
Biotechnology, Health, Surgery, Medical Devices, Paragon, Chicken feet, Foot, FNA, Surgeon, Multimedia, Bunion, Recurrence, Charcot foot, Business, Ankle, NYSE

Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced today an expansion of its soft-tissue portfolio with the launch of its Grappler Suture Anchor System.

Key Points: 
  • Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced today an expansion of its soft-tissue portfolio with the launch of its Grappler Suture Anchor System.
  • View the full release here: https://www.businesswire.com/news/home/20220517005471/en/
    The Grappler Suture Anchor System (Graphic: Business Wire)
    We are excited to launch the Grappler Soft Tissue Anchors, expanding our soft-tissue portfolio, said Paragon 28s CEO, Albert DaCosta.
  • The addition of the Grappler Suture Anchor System Stabilization System bolsters Paragon 28's soft tissue product offering, which includes the recently launched Paratrooper Plantar Plate System and R3ACT Stabilization System, as well as legacy products like TenoTac, Grappler Interference Screw System, and R3LEASE Stabilization System.
  • With this comprehensive portfolio, Paragon 28 provides its customers a broad array of innovative solutions for soft tissue stabilization and repair.

ASP Health and Planet Innovation Receive 2022 Medical Design Excellence Award

Retrieved on: 
Tuesday, May 10, 2022
Bronze Award, ROSE, PLANET, Health, ASC, Engineering, FNA, Physician, Patient, Patient safety, Anesthesia, HEALTH, Partnership, FDA, Cancer, Diagnosis, Hospital, Pressure, ASP, PI, American Society of Cytopathology, Marketing, Medtech, Society, MDEA, CEO, Technology, Research, AI, Collection, Risk, Medicine, Medical device, Pharmaceutical industry, Medical imaging, Cytopathology

EVANSTON, Ill. and IRVINE, Calif., May 10, 2022 /PRNewswire-PRWeb/ -- ASP Health, a private medical device company focused on developing and commercializing innovative sample preparation technology to enhance and expand cancer diagnosis, and Planet Innovation (PI), ASP Health's product development and commercialization partner, have received the Bronze Award in the Testing and Diagnostic Product and Systems category for their innovative, FDA-registered automated sample preparation system. The company introduced its novel system at the American Society of Cytopathology (ASC) 69th Annual Scientific Meeting in November 2021.

Key Points: 
  • The ASP Health platform was honored in the 2022 Medical Design Excellence Awards (MDEA), the premier awards program for the MedTech industry.
  • ABOUT ASP HEALTH ASP Health is a private medical device company focused on developing and commercializing innovative sample preparation technology to enhance and expand cancer diagnosis.
  • ASP Health partners with Planet Innovation , a world-class company known for creating breakthrough products and commercially successful businesses.
  • ABOUT PLANET INNOVATION Planet Innovation (PI) is a healthtech innovation and commercialization company that exists to create breakthrough products and commercially successful businesses that transform industries and have a positive impact on the world.

Paragon 28 Launches Paratrooper™ Plantar Plate System for Hammertoe and Soft Tissue Repair

Retrieved on: 
Wednesday, April 27, 2022
Health, Surgery, Other Health, Medical Devices, Paragon, Bunion, Recurrence, Hammer toe, Foot, FNA, Charcot foot, Business, JAWS, Contracture, Surgeon, Plantar plate, Chicken feet, NYSE, Ankle, Multimedia, 3D printing

Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced today an expansion of its hammertoe and soft-tissue portfolio with the launch of its Paratrooper Plantar Plate Repair System.

Key Points: 
  • Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced today an expansion of its hammertoe and soft-tissue portfolio with the launch of its Paratrooper Plantar Plate Repair System.
  • The Paratrooper Plantar Plate Systems low profile, all-suture implant provides surgeons a new and innovative approach for plantar plate repair and forefoot deformities.
  • View the full release here: https://www.businesswire.com/news/home/20220427005149/en/
    Paratrooper Plantar Plate System (Graphic: Business Wire)
    Paragon 28s CEO, Albert DaCosta, commented, Repair of the plantar plate has historically been one of the more challenging pathologies within the hammertoe sub-segment.
  • The addition of the Paratrooper Plantar Plate System bolsters Paragon 28s hammertoe product offering, which includes the TenoTac Soft Tissue Fixation System, HammerTube Hammertoe System, Mini-Monster Screw System, and JAWS Staple System.

Paragon 28 Launches R3ACT™ Stabilization System for Ankle Injuries

Retrieved on: 
Tuesday, April 19, 2022
Medical Devices, Health, Other Health, General Health, Pharmaceutical, Biotechnology, Paragon, NYSE, Ankle, Bunion, Foot, Multimedia, FNA, Recurrence, Charcot foot, Business, Chicken feet

Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced today the launch of its R3ACT Stabilization System, designed to be a simple solution that allows for multi-stage soft tissue healing following an acute or chronic syndesmotic injury to the ankle.

Key Points: 
  • Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced today the launch of its R3ACT Stabilization System, designed to be a simple solution that allows for multi-stage soft tissue healing following an acute or chronic syndesmotic injury to the ankle.
  • View the full release here: https://www.businesswire.com/news/home/20220419005422/en/
    Paragon 28s CEO, Albert DaCosta commented, Since the inception of Paragon 28, the development of a syndesmotic stabilization system for ankle injuries has been a top priority for us.
  • As a result, we believe the R3ACT Stabilization System will be a nice complement to our entire ankle fracture portfolio.
  • Based in Englewood, CO., Paragon 28, is a leading medical device company exclusively focused on the foot and ankle orthopedic market and is dedicated to improving patient lives.

Paragon 28 To Report First Quarter 2022 Financial Results on May 9, 2022, and Present at the 2022 Bank of America Healthcare Conference on May 10, 2022

Retrieved on: 
Monday, April 18, 2022
Medical Devices, Health, Paragon, Bunion, CEO, Recurrence, Foot, FNA, Charcot foot, Conference, Bank, Webcast, Chicken feet, NYSE, Ankle, Broadcasting

Paragon 28, Inc. (NYSE: FNA) (PARAGON), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced it will report financial results for the first quarter 2022 after market close on Monday, May 9, 2022.

Key Points: 
  • Paragon 28, Inc. (NYSE: FNA) (PARAGON), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced it will report financial results for the first quarter 2022 after market close on Monday, May 9, 2022.
  • The companys management will webcast a corresponding conference call beginning at 4:30 p.m. Eastern Time.
  • Investors interested in listening to the conference call may do so by dialing (844-200-6205) for domestic callers or (646-904-5544) for international callers, using conference ID: 990038.
  • Live audio of the webcast will be available on the Investors section of the companys website at: ir.paragon28.com.